The Genome Analysis Core (GAC or the Core) provides services, advice, and instrumentation for genotyping, gene expression, and epigenetic (methylation) analysis. Using two main platforms, the Sequenom MassArray and the AB 7900HT Real-Time QPCR instrument, the Core provides a variety of services at the low- to medium-throughput level important for understanding the genetics of cancer. Genotyping and mutation analyses of single nucleotide polymorphisms (SNPs) using the Sequenom MassArray are instrumental in helping scientists determine causative mutations in the germline or somatic genes, which lead to certain cancers or human diseases. Methylation analyses provided by the Sequenom MassArray assist in understanding the control of gene expression in tumor progression. A major focus of the Core's services is the use of quantitative real-time PCR (QPCR) on the 7900HT platform. Using a repository of TaqMan assays, the Core provides services for DNA copy number measurements, mRNA and miRNA expression analyses, plus training courses for members of the Helen Diller Family Comprehensive Cancer Center (Center) to learn QPCR techniques. Besides full-service options, most instrumentation is available for independent use by investigators The Center GAC works to improve access by Center members to genetic and genomic technologies. The services we offer, or propose to develop, are actively coordinated with the other UCSF genomics core facilities to avoid detrimental duplication of capacity. For example. Center members have access to extensive high throughput gene expression, genotyping, and sequencing technologies (Affymetrix and Illumina) through Core facilities at UCSF's Parnassus and Mission Bay campuses.
| Dvorak, Christopher C; Satwani, Prakash; Stieglitz, Elliot et al. (2018) Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatr Blood Cancer 65:e27034 |
| Fan, Qi Wen; Nicolaides, Theodore P; Weiss, William A (2018) Inhibiting 4EBP1 in Glioblastoma. Clin Cancer Res 24:14-21 |
| Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131: |
| Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228 |
| Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408 |
| Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279 |
| Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380 |
| Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485 |
| An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575 |
| Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3: |
Showing the most recent 10 out of 192 publications
